Hematopoietic stem cell transplantation (HSCT) is widely used to treat hematological malignancies and nonmalignant disorders. Many advances have been made in improving the success of bone marrow transplantation. However, lack available matched related or sibling donors has posed a significant challenges availability proper utilization hematopoietic patients with malignancies. The rising alterna...

successful cure of the hematological manifestations of Fanconi’s anemia (4), thousands of people worldwide have been beneficiaries of these therapeutic advantages, and to date, nearly 500 umbilical cord blood hematopoietic stem cell transplants occur annually in the United States (5). The vast majority of these hematopoietic transplants occur using publicly banked umbilical cord blood, some uti...

Ballen, K.K., Wilson, M., Wuu, J., Ceredona, A.M., Hsieh, C., Stewart, F.M., Popovsky, M.A. & Quesenberry, P.J. (2001) Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units. Bone Marrow Transplantation, 27, 7–14. Donaldson, C., Armitage, W.J., Laundy, V., Barron, C., Buchannan, R., Webster, J., Bradley, B. & Hows, J. (1999) Impact of obstetr...

Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrowtoxic doses of cytotoxic drugs with or without whole body radiation therapy. Bone marrow stem cells may be obtained from the transplant recipient (autologous HSCT) or from a donor (allogeneic HSCT). They can ...

Nowadays, the use of umbilical cord blood (UCB) stem cells is promoting for related and unrelated donor transplantation. A successful transplant happens when quality of isolated cells will be high. Therefore, in addition to yield of quantitative production, to provide safe and effective products is very important in cord blood banks, because these products have to create the conditions and resu...

Background: In this study, we examined a new two step induction protocol for improving the differentiation of human umbilical cord blood-derived mesenchymal stem cells into neural progenitor cells. Materials and Methods: Human umbilical cord blood-derived mesenchymal stem cells were first cultured in Dulbecco’s modified eagle medium supplemented with 10% fetal bovine serum in a humidified incu...

An adult woman developed polymorphic post-transplant lymphoproliferative disorder (PTLD) 58 months after unrelated cord blood transplantation. She was treated successfully with chemotherapy and radiation therapy but presented with lymphadenopathy and splenomegaly 74 months after transplantation. A lymph node biopsy confirmed the diagnosis of nodular sclerosis type Hodgkin lymphoma (classical Ho...

he lack of maternal rejection of the allogenic fetus, suggests that adaptation of the immune system occurs during normal pregnancy. Umbilical cord blood (UCB) cells have unique properties to overcome the maternal rejection of allogenic fetus. Human umbilical cord blood cells (UCBC) has been shown to be an effective source in allogenic stem cell transplantation, however there is concern due for ...

spinal cord injury (sci) is a devastating condition, with sudden loss of sensory, motor, and autonomic function distal to the level of trauma. the primary mechanical trauma causes necrosis, edema, hemorrhage, and vasospasm. a cascade of secondary pathophysiological mechanisms is induced, including ischemia, apoptosis, fluid and electrolyte disturbances, excitotoxicity, lipid peroxidation, produ...